Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.
Journal: The lancet. Diabetes & endocrinology
Published: March 18, 2025
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal: Circulation
Published: April 18, 2023
Machine learning approaches to predict the 1-year-after-initial-AMI survival of elderly patients.
Journal: BMC medical informatics and decision making
Published: November 30, 2021
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Journal: ESC heart failure
Published: October 27, 2020
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Journal: Postgraduate medicine
Published: May 06, 2020
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Journal: Advances in therapy
Published: January 28, 2020
Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Journal: Diabetes, obesity & metabolism
Published: May 30, 2019
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Journal: Circulation
Published: February 22, 2019
Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: February 15, 2019
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.
Journal: Diabetes care
Published: September 17, 2018
Physician-patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes - New findings from the global IntroDia® study.
Journal: Diabetes research and clinical practice
Published: July 30, 2018
Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study.
Journal: Diabetes research and clinical practice
Published: July 30, 2018
Last Updated: 09/26/2026